Stingless Bee Honey Protects Against Lipopolysaccharide Induced-chronic Subclinical Systemic Inflammation and Oxidative Stress by Modulating Nrf2, NF-κB and P38 MAPK
Overview
Affiliations
Background: Epidemiological and experimental studies have extensively indicated that chronic subclinical systemic inflammation (CSSI) and oxidative stress are risk factors for several chronic diseases, including cancer, arthritis, type 2 diabetes, and cardiovascular and neurodegenerative diseases. This study examined the protective effect of stingless bee honey (SBH) supplementation against lipopolysaccharide (LPS)-induced CSSI, pointing to the possible involvement of NF-κB, p38 MAPK and Nrf2 signaling.
Methods: CSSI was induced in male Sprague Dawley rats by intraperitoneal injection of LPS three times per week for 28 days, and SBH (4.6 and 9.3 g/kg/day) was supplemented for 30 days.
Results: LPS-induced rats showed significant leukocytosis, and elevated serum levels of CRP, TNF-α, IL-1β, IL-6, IL-8, MCP-1, malondialdehyde (MDA) and 8-hydroxy-2'-deoxyguanosine (8-OHdG), accompanied with diminished antioxidants. Treatment with SBH significantly ameliorated inflammatory markers, MDA and 8-OHdG, and enhanced antioxidants in LPS-induced rats. In addition, SBH decreased NF-κB p65 and p38 MAPK, and increased Nrf2 expression in the liver, kidney, heart and lung of LPS-induced rats. Furthermore, SBH prevented LPS-induced histological and functional alterations in the liver, kidney, heart and lung of rats.
Conclusion: SBH has a substantial protective role against LPS-induced CSSI in rats mediated via amelioration of inflammation, oxidative stress and NF-κB, p38 MAPK and Nrf2 signaling.
Sulaimon F, Ibiyeye R, Imam A, Oyewole A, Imam A, Shehu M Anat Cell Biol. 2024; 57(3):431-445.
PMID: 38992924 PMC: 11424567. DOI: 10.5115/acb.24.034.
Yang K, Wang Y Exp Ther Med. 2024; 27(6):256.
PMID: 38766306 PMC: 11099608. DOI: 10.3892/etm.2024.12544.
Medical-Grade Honey as a Potential New Therapy for Bacterial Vaginosis.
Lardenoije C, Riel S, Peters L, Wassen M, Cremers N Antibiotics (Basel). 2024; 13(4).
PMID: 38667044 PMC: 11047503. DOI: 10.3390/antibiotics13040368.
Jung J, Wang F, Turk A, Park J, Ma H, Ma Y Molecules. 2023; 28(22).
PMID: 38005205 PMC: 10672841. DOI: 10.3390/molecules28227484.
Understanding the prevalence, progression, and management of metabolic syndrome in Saudi Arabia.
Alshehri F Saudi Med J. 2023; 44(10):973-986.
PMID: 37777274 PMC: 10541973. DOI: 10.15537/smj.2023.44.10.20230450.